Diagnosis & Neuroimaging of Vascular Cognitive Impairment
Vascular cognitive impairment (VCI) encompasses the full spectrum of cerebrovascular-related cognitive decline, from mild impairment with preserved daily function to frank vascular dementia and mixed-etiology syndromes. VCI accounts for approximately 20% of all dementias, though this is almost certainly an underestimate given the prevalence of mixed pathologies. Community-based autopsy series demonstrate that combined AD and cerebrovascular disease is the most common pathologic combination in older individuals, and vascular brain injury lowers the threshold for clinical expression of Alzheimer disease (AD) and other neurodegenerative pathologies. Neuroimaging—particularly MRI—has transformed VCI recognition by revealing the burden of “silent” small vessel ischemic disease, cerebral amyloid angiopathy (CAA), and microinfarcts. This topic reviews the diagnostic criteria, cognitive profiles, and neuroimaging findings essential for accurate identification and classification of VCI.
Bottom Line
- Diagnostic criteria: The VASCOG criteria define mild VCI (impairment in ≥1 domain, preserved function) and major VCI/vascular dementia (functional dependence); neuroimaging evidence of cerebrovascular disease is required for a “probable” diagnosis
- Cognitive profile: Executive dysfunction and slowed processing speed are the hallmark deficits of subcortical VCI, distinguishing it from the amnestic profile of early AD
- MRI is preferred: MRI (T1, FLAIR, T2*/SWI, DWI) is superior to CT for detecting WMH, lacunar infarcts, cerebral microbleeds, and enlarged perivascular spaces
- Fazekas scale: WMH severity is graded 0–3 for periventricular and deep white matter; higher grades correlate with cognitive decline, stroke risk, and mortality
- STRIVE-2 standards: Provide harmonized terminology and definitions for MRI markers of cerebral small vessel disease
- Boston Criteria 2.0: Incorporate hemorrhagic (microbleeds, siderosis) and non-hemorrhagic (WMH multispot pattern, centrum semiovale perivascular spaces) MRI features for clinical CAA diagnosis
- Mixed dementia biomarkers: CSF/plasma biomarkers (Aβ42/40, p-tau217) help distinguish pure VCI from mixed AD-vascular pathology, guiding anti-amyloid therapy eligibility
Diagnostic Criteria for Vascular Cognitive Impairment
Diagnostic standards have evolved since the 1993 NINDS-AIREN criteria, which captured poststroke dementia but missed insidious, progressive forms of vascular-related cognitive decline. The term vascular cognitive impairment now encompasses mild impairment, vascular dementia subtypes, and mixed-etiology dementias.
| Criteria | Year | Key Features | Limitations |
|---|---|---|---|
| NINDS-AIREN | 1993 | Dementia + cerebrovascular disease on imaging + temporal relationship; “probable”/“possible” | Excluded mild VCI and subcortical SVD; high specificity but low sensitivity |
| DSM-5 Vascular NCD | 2013 | Cognitive decline in ≥1 domain; temporal link to cerebrovascular event or neuroimaging evidence | Does not specify VCI subtypes; lacks detailed neuroimaging criteria |
| AHA/ASA Statement | 2011 | Recommended 5-min and 30-min neuropsychological screening protocols; emphasized executive function | Harmonization guidelines, not formal diagnostic criteria |
| VASCOG Consensus | 2014/2018 | Mild VCI (≥1 domain impaired, function preserved) and major VCI (functional dependence); MRI required for “probable”; 4 subtypes defined | Requires neuroimaging availability; ongoing validation |
VASCOG Major VCI (Vascular Dementia) Subtypes
- Poststroke dementia: Cognitive decline within 6 months of a clinical stroke; abrupt or stepwise course; focal neurologic deficits often present; stroke doubles the risk of dementia, with hemorrhagic stroke conferring higher risk than ischemic stroke
- Subcortical ischemic vascular dementia: Progressive decline driven by diffuse small vessel disease; executive dysfunction and slowed processing speed predominate; gait disturbance and urinary symptoms common
- Multi-infarct (cortical) dementia: Cumulative effect of multiple cortical infarcts; cognitive pattern depends on infarct location; classic stepwise decline
- Mixed-pathology dementia: Coexisting cerebrovascular disease with AD, Lewy body, or other neurodegenerative pathology; the most common scenario in older adults; each additional pathology lowers the threshold for clinical dementia
Cognitive Profile & Neuropsychological Assessment
The neuropsychological signature of VCI depends on the type, location, and severity of cerebrovascular disease. Subcortical VCI preferentially disrupts frontal-subcortical circuits, producing executive dysfunction, slowed processing speed, and impaired attention with relative preservation of episodic memory and language in early stages. In contrast, strategic infarcts in regions such as the left angular gyrus, thalamus, or caudate can produce domain-specific deficits that mimic cortical neurodegenerative syndromes. Importantly, the memory deficit in VCI is typically a retrieval deficit (improved by cueing), contrasting with the encoding deficit (poor free recall and recognition) characteristic of AD. Poststroke cognitive impairment occurs in up to 60% of stroke survivors in the first year, with greater age, stroke volume, pre-existing small vessel disease, diabetes, and low education being key risk factors.
Strategic Infarct Locations and Cognitive Consequences
- Left thalamus: Verbal memory impairment, aphasia, executive dysfunction—can closely mimic AD presentation
- Left frontotemporal cortex: Aphasia, verbal memory loss; strongly associated with poststroke cognitive impairment
- Right parietal lobe: Hemispatial neglect, visuospatial dysfunction, anosognosia
- Caudate nucleus: Executive dysfunction, apathy, abulia; disrupts frontal-subcortical circuits
- Bilateral hippocampi: Severe anterograde amnesia from posterior cerebral artery territory infarcts
- Clinical significance: A single strategically located infarct can cause cognitive impairment comparable to that from diffuse small vessel disease
| Domain | Subcortical VCI | Alzheimer Disease | Useful Tests |
|---|---|---|---|
| Executive function | Early, prominent impairment | Preserved until moderate stages | Trail Making B, DKEFS, Stroop |
| Processing speed | Disproportionately slowed | Mildly slowed | Digit Symbol/Coding, TMT-A |
| Attention | Impaired; fluctuations may occur | Relatively preserved early | Digit Span, CPT |
| Episodic memory | Retrieval deficit; benefits from cueing | Encoding deficit; poor recognition | CVLT-II, RAVLT, Logical Memory |
| Visuospatial | Variable; depends on lesion location | Impaired (esp. posterior-variant) | Rey Complex Figure, Clock Drawing |
| Language | Reduced verbal fluency (phonemic) | Naming and semantic fluency decline | BNT, Category/Letter Fluency |
Clinical Features Suggestive of VCI Over AD
- Executive-predominant pattern: Disproportionate impairment in planning, multitasking, and set-shifting relative to episodic memory
- Psychomotor slowing: Timed tasks disproportionately affected; untimed performance may be near-normal
- Motor and gait signs: Shuffling gait, postural instability, focal neurologic signs, or urinary urgency
- Behavioral features: Prominent apathy, depression, and emotional lability; disinhibition with frontal involvement
- Course of decline: Stepwise deterioration (multi-infarct), insidious progression (subcortical SVD), or abrupt onset after stroke
- Vascular risk factor burden: Hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, OSA, obesity
MRI Features of Cerebral Small Vessel Disease
MRI is the preferred neuroimaging modality for VCI evaluation. The STRIVE-2 (STandards for ReportIng Vascular changes on nEuroimaging, version 2) consortium established harmonized terminology and definitions for MRI markers of cerebral small vessel disease. Essential sequences include T1 (atrophy, lacunes), T2/FLAIR (WMH), T2*/SWI (microbleeds, siderosis), and DWI (acute ischemia).
| MRI Feature | Sequence | STRIVE-2 Definition | Prevalence | Cognitive Impact |
|---|---|---|---|---|
| WMH | T2/FLAIR | White matter signal abnormalities; periventricular and/or deep subcortical | >90% by age 65 | Executive dysfunction > processing speed; greater volume → higher stroke, dementia, mortality risk |
| Lacunar infarcts | T1, FLAIR | Round/ovoid CSF-filled cavities, 3–15 mm, in deep gray/white matter | Up to 23% | Basal ganglia/thalamic location → greatest cognitive impact |
| Cerebral microbleeds | T2*/SWI | Small (≤10 mm) round hypointense hemosiderin deposits | 5–25% | Lobar → CAA; deep/infratentorial → hypertensive arteriopathy |
| Enlarged PVS | T2, T1 | CSF-isointense spaces along penetrating vessels; ≤3 mm typical | Common; increases with age | BG PVS → cerebrovascular disease; CSO PVS → CAA/AD |
| Microinfarcts | High-res T1/T2 | Microscopic ischemic foci; 50 µm to mm; often invisible on standard MRI | 24–62% at autopsy | ≥3 microinfarcts carry dementia risk comparable to Braak V–VI |
| Cortical superficial siderosis | T2*/SWI | Linear cortical surface hypointensity from hemosiderin | Rare; common in CAA | Hallmark of CAA; associated with hemorrhagic stroke risk |
Fazekas Scale for White Matter Hyperintensity Grading
The Fazekas scale grades periventricular and deep WMH separately (0–3) on FLAIR/T2 sequences. Higher Fazekas grades correlate with greater cognitive impairment, faster decline, increased stroke risk, and higher all-cause mortality. Pathologically, WMH are associated with myelin pallor, demyelination, axonal loss, inflammation, gliosis, arteriolosclerosis, venous collagenosis, and CAA. Small vessel ischemic disease begins developing in midlife, highlighting the need to address vascular risk factors early.
| Grade | Periventricular WMH | Deep/Subcortical WMH | Clinical Significance |
|---|---|---|---|
| 0 | Absent | Absent | Normal |
| 1 | Caps or pencil-thin lining | Punctate foci | Age-appropriate; minimal clinical significance |
| 2 | Smooth halo | Beginning confluence | Moderate SVD; associated with executive dysfunction and gait disturbance |
| 3 | Irregular, extending into deep WM | Large confluent areas | Severe SVD; strongly associated with VCI, stroke risk, and mortality |
Pitfalls in Interpreting White Matter Hyperintensities
- Not all WMH are vascular: Posterior (parietal-occipital) WMH can be an early feature of AD reflecting wallerian degeneration from cortical neurodegeneration rather than ischemic injury
- Normal-appearing WM injury: DTI and ASL reveal microstructural damage and reduced blood flow in tissue surrounding WMH that appears normal on conventional MRI, predicting future WMH expansion
- Multiple etiologies: WMH in older adults often reflect a combination of hypertensive arteriopathy, venous collagenosis, CAA, and neurodegenerative processes; attributing WMH to a single cause oversimplifies the pathology
- Think CADASIL: Confluent WMH disproportionate to vascular risk factors, especially with anterior temporal pole and external capsule involvement, should prompt NOTCH3 genetic testing
Boston Criteria Version 2.0 for CAA
Cerebral amyloid angiopathy involves deposition of Aβ40 in cortical and leptomeningeal vessel walls. CAA is present in approximately 48% of patients with AD and 23% of population-based older cohorts at autopsy. The Boston Criteria version 2.0 (2022) expanded the MRI diagnostic features beyond hemorrhagic signatures to include non-hemorrhagic markers, substantially improving diagnostic sensitivity. CAA-related hemorrhages are lobar in distribution, in contrast to hypertensive hemorrhages which favor the basal ganglia, thalamus, and pons.
Boston Criteria 2.0: MRI Features and Diagnostic Levels
- Hemorrhagic features (T2*/SWI): Lobar intracerebral hemorrhage, lobar cerebral microbleeds, cortical superficial siderosis, convexity subarachnoid hemorrhage
- Non-hemorrhagic features (T2/FLAIR): WMH in multispot pattern (>10 in both hemispheres, typically symmetric); severe centrum semiovale perivascular spaces (>20 in one hemisphere)
- Probable CAA: Age ≥50 + clinical presentation (ICH, TFNEs, or cognitive impairment) + ≥2 lobar hemorrhagic lesions, OR 1 hemorrhagic + 1 non-hemorrhagic feature
- Possible CAA: Age ≥50 + clinical presentation + 1 lobar hemorrhagic lesion OR 1 non-hemorrhagic feature alone
- Exclusion criteria: Other causes of bleeding must be absent; deep hemorrhagic lesions suggest hypertensive arteriopathy rather than CAA
CT vs. MRI in VCI Evaluation
Although CT is widely available and useful for excluding acute hemorrhage and mass lesions, its sensitivity for the key imaging features of VCI is markedly inferior to MRI. The VASCOG consensus recommends MRI as the preferred modality for evaluating suspected VCI. CT is appropriate only when MRI is contraindicated or in emergency settings.
| Feature | CT | MRI |
|---|---|---|
| White matter hyperintensities | Low sensitivity; seen only when severe | High sensitivity on FLAIR/T2; Fazekas grading |
| Lacunar infarcts | Moderate; misses small lesions | High sensitivity on T1, FLAIR, DWI |
| Cerebral microbleeds | Not detectable | Detected on T2*/SWI; critical for CAA |
| Perivascular spaces | Not reliably detected | Visible on T2; regional distribution aids differential |
| Superficial siderosis | Not detectable | Detected on T2*/SWI; pathognomonic for CAA |
| Acute ischemia | Low sensitivity first 12–24 h | High sensitivity on DWI within minutes |
| Brain atrophy | Gross assessment only | Volumetric quantification (NeuroQuant, Heuron) |
Perivascular Spaces and Brain Waste Clearance
The perivascular space has emerged as a critical link between cerebrovascular dysfunction and the development of neurodegenerative pathology. This fluid-filled space between the endothelial basement membrane and surrounding astrocytic end-feet serves as an integral component of the brain waste clearance system (the “glymphatic” pathway). CSF influx enters the brain parenchyma via perivascular spaces, combines with interstitial fluid and toxic solutes (including soluble Aβ and tau), and exits through dural and peripheral lymphatics—a process potentially facilitated during sleep. MR-visible perivascular spaces are presumed to be enlarged and carry diagnostic significance: greater basal ganglia PVS burden is associated with cerebrovascular disease and VCI, while greater centrum semiovale PVS burden is more closely associated with AD and CAA. Perivascular drainage may be disrupted by age-related vascular stiffening, CAA, and hypertension, providing a potential mechanism linking vascular risk factors to impaired clearance of amyloid and tau aggregates.
Role of PET Imaging in VCI
Amyloid PET is valuable in the VCI workup primarily to determine whether comorbid AD pathology is present—a distinction with major therapeutic implications in the era of anti-amyloid monoclonal antibodies. A negative amyloid PET in a patient with cognitive impairment and significant MRI small vessel disease supports a diagnosis of pure VCI, while a positive scan raises the likelihood of mixed AD-vascular pathology. Midlife cardiovascular risk factors have been associated with elevated amyloid on PET imaging more than 20 years later, and midlife dyslipidemia specifically has been linked to greater amyloid deposition. FDG-PET in pure VCI typically shows patchy, asymmetric cortical and subcortical hypometabolism, contrasting with the temporoparietal and posterior cingulate pattern of AD. Tau PET can further differentiate by demonstrating medial temporal and neocortical tau accumulation patterns specific to AD pathology.
CSF & Blood Biomarkers in Mixed Dementia
Because mixed AD-vascular pathology is the most common combination in older adults, biomarkers are critical for parsing the relative contributions of each pathology and determining eligibility for disease-modifying therapies.
| Biomarker | Pure VCI | Mixed AD + VCI | Pure AD | Clinical Utility |
|---|---|---|---|---|
| CSF Aβ42/40 | Normal | Decreased | Decreased | Identifies comorbid amyloid pathology |
| CSF p-tau181/217 | Normal | Elevated | Elevated | Distinguishes mixed from pure VCI |
| Plasma p-tau217 | Normal | Elevated | Elevated | Non-invasive screen for comorbid AD |
| NfL (CSF/plasma) | Elevated | Elevated | Elevated | Non-specific; tracks neuronal injury severity |
| Amyloid PET | Negative | Positive | Positive | Gold standard for amyloid status |
Vascular Contraindications to Anti-Amyloid Therapy
Anti-amyloid monoclonal antibodies (lecanemab, donanemab) carry risk of amyloid-related imaging abnormalities (ARIA)—both edema (ARIA-E) and hemorrhage (ARIA-H)—which share pathophysiologic mechanisms with CAA-related inflammation. Comprehensive MRI screening for vascular disease is mandatory before treatment initiation.
MRI Vascular Exclusion Criteria for Anti-Amyloid Therapy
- >4 cerebral microbleeds on T2*/SWI
- Any macrohemorrhage >10 mm in diameter
- Cortical superficial siderosis
- Significant FLAIR WMH (severe Fazekas grade)
- Multiple lacunar strokes or any major vascular territory stroke
- TIA or stroke within 12 months
- CAA-related inflammation: Asymmetric WMH with colocalized microbleeds
- APOEε4 homozygotes carry the highest ARIA risk; genotyping strongly recommended before treatment
Cardiac Disease, Carotid Stenosis, and VCI
Among cardiovascular disorders, atrial fibrillation and congestive heart failure have the strongest independent associations with cognitive impairment. Atrial fibrillation increases dementia risk most in younger individuals with longer duration. Congestive heart failure confers a 60% increase in dementia risk that is predominantly vascular in nature. High-grade carotid stenosis (≥70%) negatively affects cognition through embolization and hypoperfusion mechanisms; the CREST-2 trial demonstrated worse cognitive performance (particularly memory) in patients with asymptomatic carotid stenosis, with improved cerebral blood flow and cognition reported after carotid endarterectomy. Decreased cerebral perfusion has been independently associated with increased cognitive decline and dementia risk, most pronounced in those with greater WMH burden.
Differentiating VCI from AD and Other Dementias
Distinguishing VCI from AD and other neurodegenerative dementias requires integration of clinical history, cognitive testing, neuroimaging, and fluid biomarkers. In practice, the majority of older patients have mixed pathology, and the clinical goal is to identify relative contributions of each process to guide treatment.
Key Differentiating Features by Diagnosis
- Pure VCI: Executive/processing speed predominance; gait disturbance and motor signs; prominent MRI SVD (Fazekas ≥2, lacunes, microbleeds); stepwise or progressive course; vascular risk burden; normal AD biomarkers
- Pure AD: Episodic memory impairment with poor recognition; insidious progressive course; hippocampal and temporoparietal atrophy; positive amyloid and tau biomarkers; no focal signs until later stages
- Mixed AD + VCI: Combined features of both; memory impairment with executive dysfunction; MRI shows atrophy plus SVD; positive AD biomarkers with concurrent vascular features; the most common scenario in adults over 75
- CADASIL: Young onset (<65 years); migraine with aura; subcortical strokes; anterior temporal pole and external capsule WMH out of proportion to risk factors; confirmed by NOTCH3 genetic testing
- CAA-related cognitive impairment: Lobar microbleeds and superficial siderosis on T2*/SWI; posterior-predominant WMH; transient focal neurologic episodes; APOEε4 and ε2 associated; hemorrhagic risk precludes antiplatelet/anticoagulant therapy
Clinical Evaluation Approach
A systematic evaluation for VCI should include detailed history (cognitive trajectory, stroke events, vascular risk factors), neurologic examination (focal deficits, gait, parkinsonism, urinary symptoms), neuropsychological assessment with emphasis on executive function, and comprehensive neuroimaging.
Recommended Workup for Suspected VCI
- Neuroimaging: Brain MRI with T1, FLAIR, T2*/SWI, and DWI sequences; volumetric analysis if available; CT only if MRI is contraindicated
- Cognitive screening: MoCA preferred over MMSE (better captures executive dysfunction); formal neuropsychological testing recommended for diagnostic certainty
- Laboratory: TSH, vitamin B12, CMP, HbA1C, lipid panel; consider homocysteine, ESR, RPR as clinically indicated
- Vascular evaluation: Blood pressure assessment (including ambulatory monitoring); carotid duplex ultrasonography; ECG and echocardiography for atrial fibrillation and structural heart disease
- Biomarkers: Plasma p-tau217 or CSF Aβ42/40 and p-tau to assess for comorbid AD when mixed pathology is suspected; amyloid PET for definitive amyloid status
- Genetic testing: NOTCH3 for suspected CADASIL (disproportionate WMH, anterior temporal involvement, family history); APOE genotyping if anti-amyloid therapy is contemplated
References
- Silbert LC. Vascular cognitive impairment. Continuum (Minneap Minn). 2024;30(6, Dementia):1699-1725.
- Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2018;14(3):280-292.
- Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-260.
- Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: JACC scientific expert panel. J Am Coll Cardiol. 2019;73(25):3326-3344.
- Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration (STRIVE-2). Lancet Neurol. 2013;12(8):822-838.
- Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714-725.
- Debette S, Schilling S, Duperron MG, Larsson SC, Markus HS. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. JAMA Neurol. 2019;76(1):81-94.
- Roseborough AD, Saad L, Goodman M, et al. White matter hyperintensities and longitudinal cognitive decline in cognitively normal populations and across diagnostic categories: a meta-analysis. Alzheimers Dement. 2023;19(1):194-207.
- Corrada MM, Sonnen JA, Kim RC, Kawas CH. Microinfarcts are common and strongly related to dementia in the oldest-old: the 90+ Study. Alzheimers Dement. 2016;12(8):900-908.
- Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83.
- El Husseini N, Katzan IL, Rost NS, et al. Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2023;54(6):e272-e291.
- Jakel L, De Kort AM, Klijn CJM, Schreuder FHBM, Verbeek MM. Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis. Alzheimers Dement. 2022;18(1):10-28.
- Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377.
- Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171-186.
- Wolters FJ, Zonneveld HI, Hofman A, et al. Cerebral perfusion and the risk of dementia: a population-based study. Circulation. 2017;136(8):719-728.
- Lazar RM, Wadley VG, Myers T, et al. Baseline cognitive impairment in patients with asymptomatic carotid stenosis in the CREST-2 trial. Stroke. 2021;52(12):3855-3863.
- Romero JR, Pinheiro A, Aparicio HJ, et al. MRI-visible perivascular spaces and risk of incident dementia: the Framingham Heart Study. Neurology. 2022;99(23):e2561-e2571.
- Gottesman RF, Schneider ALC, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443-1450.